MannKind Corp (NASDAQ: MNKD)

MannKind Corporation is a biotechnology company involved in the discovery, development and commercialization of innovate therapies for diabetes and cancer. The best known product candidate of MannKind is AFREZZA which is an inhalable insulin product. It is also working on the MedTone and Dreamboat inhalers for delivery of the drug.

The company will be the second one to launch an inhalable insulin product after Pfizer’s Exubera. Exubera was one of the most expensive failures of the entire healthcare sector. The drug saw pretty poor sales due to concerns about the effect it had on the lungs.

The market’s perception of the success of AFREZZA is the primary catalyst driving the share price of MannKind. The share price has fluctuated between $1.5 and $5.5 during the last one year. MannKind has been rallying since February, and the price has appreciated by approximately 110%. During the last six months, insiders have purchased approximately 40 million shares of the company. This has increased insider holdings by 95%. During the same period, institutional investors have also increased their holdings by 14%. Despite the 110% rally, MannKind is still trading below its mean sell side target price of $6.1 and is a strong buy.

http://beta.fool.com/smartequity/2013/05/22/2-biotechs-to-avoid-1-to-buy-3/35087/